NxStage Medical, Inc. (NASDAQ:NXTM) Analyst Rating Update - Investor Newswire Print

Wall Street analysts polled by Zacks Research have given NxStage Medical, Inc. (NASDAQ:NXTM) a rating of 2 on a consensus basis. Using a simplified scale where 1 is a Strong Buy and 5 a Strong Sell, this is the average number of the 4 brokerages surveyed. The stock had a rating of 2 when analyst ratings were averaged three months ago.

The covering analysts have a one year price objective of $21 on NxStage Medical, Inc. (NASDAQ:NXTM). The most bullish brokerage firm sees the stock heading to $24 , while the most conservative estimate has an objective of $15.

Earnings Look Wall Street will be paying close attention when NxStage Medical, Inc. reports their next quarterly earnings report on 2015-08-06. Analysts polled by Zacks are expecting earnings per share of $-0.1 for the period ending 2015-06-30. This is the consensus number based on the 4 broker predictions taken into consideration. On a longer term basis, sell-side analysts who project long term growth are expecting earnings of $18.33. This is the three to five year estimate for both earnings and sales. Most recently NxStage Medical, Inc. reported actual earnings of $0 per share for the quarter ending on 2015-03-31. The actual reported number was $0.11 away from what analysts had expected, yielding a surprise factor of 100%. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.

...